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ABSTRACT
ObjectiveTo determinetheefficacy of statintreatment on
risk of coronary heart disease in patients with familial
hypercholesterolaemia.
Design Cohort study with a mean follow-up of 8.5 years.
Setting 27 outpatient lipid clinics.
Subjects 2146 patients with familial
hypercholesterolaemia without prevalent coronary heart
disease before 1 January 1990.
MainoutcomemeasuresRiskofcoronaryheartdiseasein
treatedand“untreated”(delayinstartingstatintreatment)
patients compared with a Cox regression model in which
statin use was a time dependent variable.
Results In January 1990, 413 (21%) of the patients had
started statin treatment, and during follow-up another
1294 patients (66%) started after a mean delay of
4.3 years. Most patients received simvastatin (n=1167,
33 mg daily) or atorvastatin (n=211, 49 mg daily). We
observed an overall risk reduction of 76% (hazard ratio
0.24 (95% confidence interval 0.18 to 0.30), P<0.001). In
fact, the risk of myocardial infarction in these statin
treated patients was not significantly greater than that in
an age-matched sample from the general population
(hazard ration 1.44 (0.80 to 2.60), P=0.23).
Conclusion Lower statin doses than those currently
advised reduced the risk of coronary heart disease to a
greater extent than anticipated in patients with familial
hypercholesterolaemia. With statin treatment, such
patients no longer have a risk of myocardial infarction
significantlydifferent from thatof the generalpopulation.
INTRODUCTION
Familial hypercholesterolaemia is a monogenic dis-
order associated with a greatly increased risk of
coronary heart disease.
1 Statins are first choice treat-
ment for all patients with the condition.
2 Placebo
controlled trials were not carried out in these patients
when statins were introduced, as it was considered
unethical to withhold causal treatment from patients
withaninbornerroroflipidmetabolism.
3Wetherefore
lack estimates of the true efficacy of statin treatment in
such patients. The results of the atorvastatin versus
simvastatin on atherosclerotic progression (ASAP)
studyhavesuggestedthatweshouldtreatsuchpatients
preferably with potent statins to maximally decrease
low density lipoprotein (LDL) cholesterol concentra-
tions and induce regression of atherosclerosis.
45In the
recently published ENHANCE study, adding ezeti-
mibe to the highest dose of simvastatin resulted in
substantial further reductions of LDL cholesterol
concentrations and high sensitivity C reactive protein
levels but did not further reduce the carotid intima-
media thickness.
6 One possible explanation for these
results is that patients with familial hypercholesterol-
aemia are currently treated optimally with statins,
resulting in delipidated arterial walls of normal
thickness, and, therefore, further lowering of LDL
cholesterol levels has no beneficial effect. In two
observationalstudies,seculartrendssuggestthatstatins
have roughly halved the risk of coronary heart disease
in patients with familial hypercholesterolaemia.
78
However,theexactprognosisoftreatedasymptomatic
patients remains unknown, and this lack of hard
endpoint data has, for example, limited access to life
insurance.
9
In this study we investigated the effect of statins on
the risk of incident coronary heart disease in patients
with familial hypercholesterolaemia, using the varia-
tion in the time of starting statin treatment to mimic a
clinical trial.
METHODS
Study population
During 1989-2002, we recruited a cohort of 2400
patients with familial hypercholesterolaemia from 27
lipid clinics as described previously.
10 We reviewed
medicalrecordstoestablishextensivephenotypicdata
including anthropometric measures, cardiovascular
events, and use of lipid lowering drugs.
11
In the present study, we chose 1 January 1990, just
after the first statin (simvastatin) became available in
the Netherlands, as the start point. We excluded
patients who already had coronary heart disease by
1990 to mimic a controlled primary prevention trial
starting at the introduction of the first statin. We
determined serum lipid concentrations in fasting
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least six weeks, and calculated LDL cholesterol
concentrations using the Friedewald formula.
12
In addition, we compared the risk of incident
myocardial infarction in patients with familial hyper-
cholesterolaemia with that in the general population.
For this analysis, we selected patients with familial
hypercholesterolaemiawhowereolderthan55yearsat
1 January 1990 and a selection of the population in the
Rotterdam study matched as a group for age and sex.
The Rotterdam study is a large population based,
prospective, follow-up study starting in 1990 assessing
the disease burden in elderly people.
13
Outcome measures
Wedefinedcoronaryheartdiseaseinour studycohort
as at least one of the following:
 Myocardial infarction, proved by at least two of
the following:
Classic symptoms (>15 minutes)
Specific electrocardiographic abnormalities
Elevated cardiac enzymes (>2×upper limit of
normal)
 Percutaneous coronary intervention or other
invasive procedures
 Coronary artery bypass grafting
 Angina pectoris, diagnosed as classic symptoms
in combination with at least one unequivocal
result of one of the following:
Exercise test
Nuclear scintigram
Dobutamine stress ultrasound scan
>70% stenosis on a coronary angiogram.
In the Rotterdam study, no data on angina were
available. We therefore chose to study myocardial
infarctionastheendpointinthisanalysis.Patientswith
percutaneous transluminal coronary angioplasty,
coronary bypass grafting, or myocardial infarction
were excluded from the sample of patients from our
cohort and as from the selected population from the
Rotterdam study.
Statistical analysis
We compared patients’ general characteristics using
analysisofvarianceforcontinuousvariablesandχ
2test
for categorical variables.We analysedlipid concentra-
tions, after adjustment for age and sex, with multiple
linear regression analyses. We calculated absolute risk
by taking into account whether statin use was started
beforetheonsetofcoronaryheartdisease.Thenumber
of coronary events among statin treated and untreated
patients was divided by the total event-free survival.
Event-freesurvivaltimewasdefinedastheperiodfrom
1 January 1990 to the date of first coronary event,
death, or censoring at the end of our observation.
We also compared survival among treated and
untreated patients using the Kaplan-Meier survival
method. In this analysis, we considered people to be
untreated when they had not taken a statin for longer
than one month before a coronary event or censoring.
All patients who received a statin during follow-up for
more than a month before an event or censoring were
considered as treated.
We performed separate analyses for patients older
than 55 years to compare them with the selected
population from the Rotterdam study. Since the
maximum follow-up in our cohort was 12 years, we
chose 2002 as the end point in the Rotterdam study as
well.
We used the Cox proportional hazard model to
estimatetheriskofcoronaryheartdiseaseamongstatin
treated patients compared with untreated patients.
Since both groups had variable periods without statin
treatment, we analysed statin treatment as a time
dependentvariable.Thisvariablewasequaltozerofor
the time statins were not used, and 1 for the time from
start of statin treatment to the date of first coronary
event or censoring. In the primary model, we adjusted
the analyses for sex and year of birth.
In additional models we adjusted for other classic
risk factors (see table 2). We performed subgroup
analyses stratified by previously identified risk factors
to define effect differences. For LDL cholesterol
concentration, we used the median value to split the
total population in two subpopulations. We classified
high density lipoprotein (HDL) cholesterol concentra-
tion according to our normal laboratory values:
<0.9 mmol/l for males, <1.1 mmol/l for females. To
test for lifestyle improvements occurring at the start of
statin treatment, we adjusted the Cox proportional
hazardmodelforsmokingcessationwithin sixmonths
after the start of statin treatment. We tested whether
deselection of worst cases occurred by adding the
patients who were never treated with statins to the
treated group as if they had started treatment on 1
January 1990 and repeated the time dependent Cox
proportional hazard analysis.
RESULTS
Of the 2400 patients recruited, we excluded 254 who
already had coronary heart disease by 1990. We
excludedafurther188patientsbecausethetypeoflipid
lowering treatment or the date of starting statin
Excluded (n=262):
  Coronary heart disease before 1990 (n=254)
  Lost to follow-up before 1990 (n=8)
Excluded (n=188):
  Type of treatment unknown (n=73)
  Start date of treatment unknown (n=115)
Started statin treatment in January 1990 (n=413)
Started statin treatment during follow-up (n=1294)
Did not receive statins (n=243)
Patients with familial hypercholesterolaemia (n=2400)
Available for prospective study  (n=2138)
Included in primary analysis  (n=1950)
Fig 1 | Flow of patients through study
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sufficientdataondruguse(fig1).InJanuary1990,413
patients were treated with a statin, and a further 1294
patients were prescribed statins during follow-up. The
mean delay in starting statin use was 4.3 years (SD
3.3 years). The 196 patients who were excluded
because of missing data or loss to follow-up had
serum LDL cholesterol concentrations 1.14 mmol/l
higher than those of the included patients. We did not
find other differences between these groups.
The patients who immediately received statin
treatment in 1990 were on average 3.5 years older
thanthepatientswhostartedstatintreatmentlater,had
higher total and LDL cholesterol concentrations (both
P<0.001), had lower HDL cholesterol levels (P=0.02),
and were significantly more likely to be hypertensive
than the other patients (table 1). Twenty eight patients
stopped taking statins for unreported reasons.
The meanfollow-uptimewas 8.5years (SD3.1years).
During 7473 person years of statin treated patients and
9319personyearsofuntreatedpatients,408patientshad
an incident coronary event, of whom 161 patients had
been using statins for an average 3.4 years (median
2.7 years, range 1 month to 11.6 years). Most patients
(n=1167)usedsimvastatinwithameandoseof33mg(SD
20 mg), leading to 44% (SD 16%) lower LDL cholesterol
concentrations compared with before they started statin
treatment.Afurther211patientsusedatorvastatinwitha
m e a nd a i l yd o s eo f4 9m gp r o v i d i n gar e d u c t i o ni nL D L
cholesterol level of 49% (SD 15%). Less commonly used
statins were pravastatin and fluvastatin. During statin
treatment the mean total cholesterol concentration was
5.9 mmol/l (SD 1.2 mmol/l), mean LDL cholesterol was
4.0 mmol/l (SD 1.2), and mean HDL cholesterol was
1.28 mmol/l (SD 0.41).
In familial hypercholesterolaemia, the absolute risk
of first onset of coronary heart disease was 11/1000
person years in statin treated patients compared with
119/1000 person years in untreated patients. Incident
coronary heart disease occurred at younger age in
untreated patients (48.6 v 50.9 years, P=0.05). The
treated group had a significantly better event-free
survival (P<0.001, fig 2). After adjustment for year of
birth and sex, statin treated patients had a 76%
reduction in risk of coronary heart disease compared
with untreated patients (hazard ratio 0.24 (95%
confidence interval 0.18 to 0.30), P<0.001). Further
adjustment for baseline characteristics such as smok-
ing, HDL and LDL cholesterol concentrations, dia-
betes,andhypertensionresultedinanoverall82%risk
reduction (hazard ratio 0.18 (0.13 to 0.25), P<0.001)
(table 2).
As expected, men had a 2.5 times greater risk of
coronary heart disease than women (95% confidence
interval 2.1 to 3.1, P<0.001). Whether women with
familial hypercholesterolaemia benefit from statins as
mendoisstillunderdebate,
14andwethereforestudied
them separately. The women taking statins had a 79%
reduction in risk of coronary heart disease compared
with women not taking statins (hazard ratio 0.21 (0.13
to 0.34), P<0.001); the men had an 83% risk reduction
(hazard ratio 0.17 (0.11 to 0.26), P<0.001) (table 2).
Patients who developed coronary heart disease had
higher serum LDL cholesterol concentrations before
treatment than did those without coronary heart
disease (7.5 mmol/l v 7.2 mmol/l, P=0.03). During
statintreatment,however,LDLcholesterollevelswere
identical among patients with and without coronary
heart disease (4.1 mmol/l v 4.0 mmol/l, P=0.38).
Classicriskfactorswere,asexpected,morecommonin
patients with coronary heart disease. The subgroup
analyses in fig 3 suggest that the efficacy of statin
treatmentdidnotsubstantially differbetweensmokers
and non-smokers, between patients with or without
diabetes, and between patients with or without
hypertension. However, the size of the subgroups
were too small for meaningful analyses.
Of all 1288 patients who had ever smoked, 333 had
stopped before 1990. A total of 407 statin users never
smoked, and 388 had stopped before statin treatment
wasstarted.Afurther105patients(10% ofall thosefor
Table 1 |Generalcharacteristicsofpatientswithfamilialhypercholesterolaemia bytheir receipt
of statin treatment in January 1990. Values are numbers (percentages) of patients unless
stated otherwise
Taking statins
(n=413)
Not taking statins
(n=1537)
P value of
difference
Men 197 (48) 727 (47) 0.89
Ever smoked 281 (77) 1007 (72) 0.09
Hypertension 47 (11) 48 (3) <0.01
Diabetes 6 (1) 5 (0.3) 0.06
Mean (SD) age at first visit to lipid clinic
(years)
43.3 (13.3) 43.8 (12.3) 0.36
Mean (SD) age at 1 January 1990 (years) 41.7 (13.2) 38.2 (12.5) <0.001
Mean (SD) body mass index (kg/m
2) 24.8 (3.5) 25.1 (3.5) 0.18
Mean(SD)totalcholesterolconcentration
(mmol/l)
10.1 (1.9) 9.0 (1.9) <0.001
Mean (SD) LDL cholesterol concentration
(mmol/l)
8.0 (1.9) 6.9 (1.8) <0.001
Mean (SD)HDL cholesterolconcentration
(mmol/l)
1.13 (0.34) 1.19 (0.37) 0.02
Mean (SD) triglyceride concentration
(mmol/l)
1.45 (0.71) 1.58 (0.48) 0.007
LDL=low density lipoprotein. HDL=high density lipoprotein.
All lipid concentrations are without statin treatment and adjusted for sex and year of birth.
Follow-up (years)
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Fig 2 | Kaplan-Meier curve estimates of cumulative coronary
heart disease-free survival among patients with familial
hypercholesterolaemia according to statin treatment (P<0.001
for difference)
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within six monthsofstartingstatin treatment.To testif
lifestyle improvement related to the start of statin
treatment could explain why smokers showed a larger
risk reduction with statins, we adjusted for smoking
cessation within six months of the start of statin
treatment, but this did not materially change the effect
of statin treatment on coronary heart disease risk
(hazard ratio 0.20 (0.15 to 0.26), P<0.001). Unfortu-
nately,bodymassindexandwaistcircumferencewere
not measured during follow-up.
A total of 243 patients in our cohort were never
treated with statins. We performed an additional
analysis adding those patients to the treatment group,
as if statin treatment had started on 1 January 1990, to
estimate the effect of an intention to treat analysis.The
hazard ratio was even lower under these assumptions
(data not shown).
We finally compared the risk of myocardial infarc-
tion in patients with familial hypercholesterolaemia
whowereolderthan55years(n=261,64men)withthat
in 1975 people in a subgroup of the participants in the
Rotterdamstudy.Themeanageinbothsubgroupswas
61.6 years and both had 24.5% men as a result of
stratified selection from the Rotterdam study. The
absolute risk of myocardial infarction was 6.7/1000
person years in our statin treated patients, 60.5/1000
person years in our untreated patients, and 4.1/1000
person years in the sample from the Rotterdam study.
Event-freesurvivalofourstatintreatedpatientswasnot
significantlydifferentfromthatoftheRotterdamstudy
sample (log rank test P=0.07), whereas our untreated
patients clearly had a higher risk of coronary heart
disease(logranktestP<0.001)(fig4).Afteradjustment
for year of birth and sex, the point estimate of risk of
myocardial infarction in our treated patients with
familial hypercholesterolaemia was higher than the
risk in the subgroup of the Rotterdam study, but this
was not significant (hazard ratio 1.44 (0.80 to 2.60),
P=0.23),whereas the risk in ouruntreated patientswas
8.7 times higher (hazard ratio 8.69 (4.77 to 15.82),
P<0.001).
DISCUSSION
We report here that relatively modest doses of statins
reducedthe riskof coronaryheartdiseasebyabout80%
inpatientswithfamilialhypercholesterolaemia.Thisisa
much more pronounced reduction than was anticipated
based on secular trends in earlier studies.
78 We also
observed that statin treated patients older than 55 years
had a risk of myocardial infarction approaching that of
the general population. Finally, men and women
experienced similar risk reductions in our study.
Strengths and weaknesses of our study
Ourfollow-upstudyhasanumberoflimitations.Firstly,
it was observational and not a randomised study.
Therefore, the patients who started treatment immedi-
ately in 1990 may have represented a selected subgroup
with more severe risk: they were selected first because
they had further progressed in their disease process. If
thiswereso,itwouldhaveresultedinahigherriskforthe
treated group compared with a randomised trial that
distributed the risks equally. However, it seems unlikely
that we have underestimated the risk reduction as the
effect was unexpectedly large.
Secondly, it could be argued that our approach
exaggerates the effect of the treatment, because our
study was not placebo-controlled. Patients might have
improved their lifestyle in conjunction with starting
statin treatment. However, adjustment for smoking
cessation within six months after the start of treatment
(as a proxy for lifestyle improvement) did not change
the effect of statin treatment.
Table 2 |Effect of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia by sex
Model I Model II Model III Model IV
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
All patients (n=1950) 0.24 (0.18 to 0.30) <0.001 0.22 (0.17 to 0.28) <0.001 0.20 (0.15 to 0.27) <0.001 0.18 (0.13 to 0.25) <0.001
Men (n=924) 0.20 (0.15 to 0.28) <0.001 0.20 (0.14 to 0.28) <0.001 0.16 (0.11 to 0.25) <0.001 0.17 (0.11 to 0.26) <0.001
Women (n=1026) 0.30 (0.20 to 0.43) <0.001 0.25 (0.17 to 0.37) <0.001 0.28 (0.18 to 0.43) <0.001 0.21 (0.13 to 0.34) <0.001
Model I=adjusted for sex and year of birth. Model II=adjusted for sex, year of birth, and smoking status. Model III=adjusted for sex, year of birth, and low-density lipoprotein cholesterol
concentration without statin treatment. Model IV=adjusted for sex, year of birth, smoking status, high density lipoprotein and low-density lipoprotein cholesterol concentrations, diabetes,
and hypertension.
Never smokers (n=475)
Ever smokers (n=1288)
No diabetes (n=1859)
Diabetes (n=90)
No hypertension (n=1722)
Hypertension (n=162)
Serum LDL cholesterol <7.0 mmol/l (n=863)
Serum LDL cholesterol >7.0 mmol/l (n=788)
HDL cholesterol low risk* (n=1772)
HDL high risk† (n=162) 
LDL=low density lipoprotein. HDL= high density lipoprotein
* Low risk serum concentrations: women >1.1 mmol/l, men >0.9 mmol/l
† High risk serum concentrations: women <1.1 mmol/l, men <0.9 mmol/l
0.05 0.10 0.20 0.50 1.0
Subgroup Hazard ratio (95% CI)
Fig 3 | Subgroup analyses for reduction in risk of coronary heart disease in patients with familial
hypercholesterolaemia by statin use in a time dependent analysis. Smoking, diabetes, and
hypertension were compared based on having ever been present. LDL cholesterol concentration
was split based on the median value, and HDL cholesterol level split based on normal laboratory
values. Hazard ratio (95% CI) by statin use is shown on a logarithmic scale
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dependent variable, whereas an intention to treat
analysis might have yielded smaller risk reductions.
We analysed the 28 patients who stopped statin
treatment as if they had stayed on treatment, in line
with an intention to treat analysis. We also made an
analysis in which all patients who were never treated
with statins were added to the treated group as if they
hadstartedtreatmenton1January1990,toestimatethe
effectthatanintentiontotreatanalysiscouldhavehad:
thisshowedanevenlargereffect.Althoughthisvalueis
aroughestimationsensitivetochoiceofdateofstartof
treatment, the decrease in hazard ratio indicates that
ourresultsarenotoverestimatingtheeffectasaresultof
deselection of worst cases.
Although some of the weaknesses associated with
lack of randomisation have been addressed, there is
always the danger that unrecognised confounding
factors, for which we made no adjustment, might
have affected our results.
Comparison with other studies
The large risk reduction and the overlap of the event-
freesurvivalbetweenthetreatedpatientsandasample
of the general population (from Rotterdam study)
suggest that statin treatment has profoundly improved
the prognosis for familial hypercholesterolaemia.
Two previous studies have investigated this issue. A
study in the United Kingdom compared mortality in
patients with familial hypercholesterolaemia with that
in the general population before and after the
introduction of statins.
7 Their results suggested that
statins did indeed reduce mortality, but that mortality
was still higher than in the general population. Exact
informationaboutthestartdateofstatintreatmentwas
not available, however, suggesting there might have
been an unrecognised delay in statin initiation similar
to what we found in the Netherlands.
In a much smaller study, 214 statin treated patients
withfamilialhypercholesterolaemiastillhadincreased
risk of cardiovascular disease.
8 As suggested by the
high frequency of premature cardiovascular disease
(45%) in first degree relatives, the patients of this study
might have been selected preferentially for severe risk
of coronary heart disease. Moreover, statin treatment
was not assessed against untreated familial hyper-
cholesterolaemia and not in a time dependent fashion.
The latter may have resulted in underestimation of the
statin effect because of misclassification of periods
without treatment. In contrast, in our study, we
prospectivelycomparedtreatedanduntreatedpatients
with familial hypercholesterolaemia as well as the
general population in a direct manner and in the same
calendar period.
Implications of findings
The standard treatment used currently is more
aggressive than that used in our study: current
regimens use simvastatin and atorvastatin doses up to
80 mg daily.
24It should be emphasised, however, that
in our study we excluded all prevalent cases, thereby
restrictingourstudytoprimaryprevention.Ourresults
cannotbeextrapolatedtosecondaryprevention,which
may require more aggressive treatment.
Supportforoptimaltreatmentwithstatinscanalsobe
deduced from the results of the ENHANCE study:
patients with familial hypercholesterolaemia had
normal carotid intima-media thickness at baseline,
and even simvastatin 80 mg alone prevented thicken-
ing of the arterial wall.
6
In previous studies we tested statin treatment of
children with familial hypercholesterolaemia and
showed attenuation of progression of carotid intima-
media thickness.
1516 Our present study suggests that
starting aggressive treatment during early childhood, as
currently done and advised by the American Academy
of Pediatrics, is probably not necessary to reduce
coronary heart disease risk.
17 Although atherosclerosis
is present in children, this process is to a certain extent
reversible,asshownbytheclosetonormalintima-media
thicknesses at baseline in the ENHANCE trial and our
findings in the present study. In both studies, statin
treatment was initiated after childhood. It is probably
safe to limit statin treatment of children with hetero-
zygous familial hypercholesterolaemia to those whose
Follow-up (years)
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Fig 4 | Kaplan-Meier curve estimates of cumulative myocardial
infarct-free survival among patients with familial
hypercholesterolaemia older than 55 years according to statin
treatment compared with a sample from the general
population (Rotterdam study). (P<0.001 for difference between
untreated patients and general population; P=0.07 for
difference between treated patients and general population)
WHAT IS ALREADY KNOWN ON THIS TOPIC
Statins are the first line treatment for familial
hypercholesterolaemia, but their efficacy is unknown
because hard end points were not studied in placebo
controlled trials
WHAT THIS STUDY ADDS
Lowerstatindosesthancurrentlyadvisedreducedcoronary
heart disease risk by 80% in patients with familial
hypercholesterolaemia
Statintreatedpatientsolderthan55yearshadasimilarrisk
of myocardial infarction as did a sample from the general
population of the same age
RESEARCH
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heart disease.
In conclusion, our data show that lower statin doses
than currently advised result in impressive reductions
of coronary heart disease risk in patients with familial
hypercholesterolaemia. These findings warrant an
immediate start of statin treatment after familial
hypercholesterolaemia has been diagnosed since such
treatmentleadstonearnormalisationofcoronaryheart
disease risk.
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